Erianin induces apoptosis and pyroptosis via MAPK/ERK and PI3K/Akt pathways and synergizes with anlotinib in anaplastic thyroid carcinoma
Collectively, our study demonstrates that erianin exerts potent anti-tumor activity in ATC by simultaneously inhibiting the MAPK/ERK and PI3K/Akt signaling pathways, thereby inducing apoptosis and GSDME-dependent pyroptosis. Furthermore, the synergistic interaction between erianin and anlotinib significantly enhances therapeutic efficacy. These findings position erianin as a promising candidate for the treatment of ATC, offering novel therapeutic insights and supporting further clinical investigations.
Authors
- Ruxue Liu
- Yin Liu (ORCID: https://orcid.org/0000-0002-3522-8967)
- Yayun Wang (ORCID: https://orcid.org/0000-0002-0397-0390)
- Qiaonan Zhang
- Jiawei Liu (ORCID: https://orcid.org/0000-0001-9940-6366)
- Zhen Yang (ORCID: https://orcid.org/0000-0001-8293-3581)
- Ming Gao (ORCID: https://orcid.org/0000-0002-3182-4331)
- Jie Hao (ORCID: https://orcid.org/0000-0002-0273-8047)
- Minghan Qiu
- Zhanhua Gao
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Tianjin Nankai Hospital (CN)
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.3389/fphar.2025.1596873
- Citations
- 2
- Primary Topic
- Phytochemistry and Biological Activities
- Type
- article
- Field-Weighted Citation Impact
- 3.50